Basabele Ngalo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Basabele Ngalo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Blessing Atim Aderibigbe
Department of Chemistry, Alice Campus, University of Fort Hare, Alice 5700, South Africa
1 shared publication - Olwethu Poswayo
Department of Chemistry, Nelson Mandela University, Gqeberha 6001, South Africa
1 shared publication - Sendibitiyosi Gandidzanwa
Department of Chemistry, Nelson Mandela University, Gqeberha 6001, South Africa
1 shared publication - Sibusiso Alven
Department of Chemistry, Nelson Mandela University, Gqeberha 6001, South Africa
1 shared publication - Tatenda Madanhire
Department of Chemistry, University of South Africa, Johannesburg, Gauteng, South Africa, unisa.ac.za
1 shared publication - Zenixole Richman Tshentu
Nelson Mandela University
1 shared publication
Latest Publications
- Open Access
- 3 September 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (9) , 1162
Platinum Group Metals Nanoparticles in Breast Cancer Therapy
Despite various methods currently used in cancer therapy, breast cancer remains the leading cause of morbidity and mortality worldwide. Current therapeutics face limitations such as multidrug resistance, drug toxicity and off-target effects, poor drug bioavailability and biocompatibility, and inefficient drug delivery. Nanotechnology has emerged as a promising approach to cancer diagnosis, imaging, and therapy. Several preclinical studies have demonstrated that compounds and nanoparticles formulated from platinum group metals (PGMs) effectively treat breast cancer. PGMs are chemically stable, easy to functionalise, versatile, and tunable. They can target hypoxic microenvironments, catalyse the production of reactive oxygen species, and offer the potential for combination therapy. PGM nanoparticles can be incorporated with anticancer drugs to improve efficacy and can be attached to targeting moieties to enhance tumour-targeting efficiency. This review focuses on the therapeutic outcomes of platinum group metal nanoparticles (PGMNs) against various breast cancer cells and briefly discusses clinical trials of these nanoparticles in breast cancer treatment. It further illustrates the potential applications of PGMNs in breast cancer and presents opportunities for future PGM-based nanomaterial applications in combatting breast cancer.
- 3 September 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (9) , 1162
Open AccessPlatinum Group Metals Nanoparticles in Breast Cancer Therapy
Despite various methods currently used in cancer therapy, breast cancer remains the leading cause of morbidity and mortality worldwide. Current therapeutics face limitations such as multidrug resistance, drug toxicity and off-target effects, poor drug bioavailability and biocompatibility, and inefficient drug delivery. Nanotechnology has emerged as a promising approach to cancer diagnosis, imaging, and therapy. Several preclinical studies have demonstrated that compounds and nanoparticles formulated from platinum group metals (PGMs) effectively treat breast cancer. PGMs are chemically stable, easy to functionalise, versatile, and tunable. They can target hypoxic microenvironments, catalyse the production of reactive oxygen species, and offer the potential for combination therapy. PGM nanoparticles can be incorporated with anticancer drugs to improve efficacy and can be attached to targeting moieties to enhance tumour-targeting efficiency. This review focuses on the therapeutic outcomes of platinum group metal nanoparticles (PGMNs) against various breast cancer cells and briefly discusses clinical trials of these nanoparticles in breast cancer treatment. It further illustrates the potential applications of PGMNs in breast cancer and presents opportunities for future PGM-based nanomaterial applications in combatting breast cancer.